Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Tabla 1. Evolución de las cifras de colesterol tras inicio de tratamiento con lorlatinib
Tabla 2. Recomendaciones de tratamiento de las dislipemias secundarias a lorlatinib
Show moreShow less
Resumen
Los anticuerpos monoclonales anti-PCSK9 han demostrado reducción de eventos cardiovasculares en pacientes con enfermedad vascular ateroesclerótica1. Sin embargo, no está descrito su uso en el tratamiento de la dislipemia secundaria a lorlatinib, un inhibidor competitivo de la quinasa del linfoma anaplásico de tercera generación, indicado en cáncer de pulmón no microcítico avanzado ALK+.
Palabras clave:
Evolocumab
Lorlatinib
Cáncer de pulmón no microcítico
Tratamiento
Seguridad
Abstract
Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer.
Keywords:
Evolocumab
Lorlatinib
Non-small-cell lung cancer
Therapy management
Safety
Article
These are the options to access the full texts of the publication Clínica e Investigación en Arteriosclerosis (English Edition)
Subscriber
Subscribe
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail